Adult-onset Still's disease secondary prevention

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Adult-onset Still's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adult-onset Still’s Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Adult-onset Still's disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Template:Adult-onset Still's disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adult-onset Still's disease secondary prevention

CDC on Template:Adult-onset Still's disease

Template:Adult-onset Still's disease in the news

Blogs on Template:Adult-onset Still's disease

Risk calculators and risk factors for Template:Adult-onset Still's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.

Secondary Prevention

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.[1]

References

  1. Nishina N, Kaneko Y, Kameda H, Takeuchi T (May 2015). "The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study". Mod Rheumatol. 25 (3): 401–4. doi:10.3109/14397595.2014.973659. PMID 25401229.

Template:WH Template:WS